
Germany has granted marketing authorisation to Exilby (VER-01) for the treatment of chronic low back pain with a neuropathic component, …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

